Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08), Zacks reports.
Nuvectis Pharma Price Performance
Shares of Nuvectis Pharma stock traded down $0.02 during trading hours on Friday, reaching $6.69. The company's stock had a trading volume of 28,728 shares, compared to its average volume of 114,701. The firm has a 50 day moving average price of $6.26 and a 200-day moving average price of $6.41. Nuvectis Pharma has a one year low of $4.44 and a one year high of $12.10. The stock has a market cap of $129.26 million, a P/E ratio of -5.77 and a beta of 0.22.
Wall Street Analyst Weigh In
Separately, HC Wainwright reduced their target price on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday.
Read Our Latest Analysis on NVCT
Insider Transactions at Nuvectis Pharma
In other news, major shareholder Marlio Charles Mosseri purchased 240,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were bought at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now owns 2,884,121 shares of the company's stock, valued at approximately $14,420,605. This trade represents a 9.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have acquired a total of 261,500 shares of company stock worth $1,300,825 in the last three months. Insiders own 35.78% of the company's stock.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Recommended Stories
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
